Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Expert Opinion on Pharmacotherapy|June 13, 2017
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myelomaKlaus Podar, Martin Pecherstorfer
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C Anderson
Cancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C Anderson
Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C Anderson
Cell Cycle (Georgetown, Tex.)|March 14, 2007
Inhibition of VEGF signaling pathways in multiple myeloma and other malignanciesKlaus Podar, Kenneth C Anderson
Expert Opinion on Biological Therapy|September 1, 2017
Adoptive cell therapy in multiple MyelomaSonia Vallet, Martin Pecherstorfer, Klaus Podar
Cancer Treatment and Research|October 4, 2016
Targeting the Bone Marrow MicroenvironmentMichele Moschetta, Yawara Kawano, Klaus Podar
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Inhibition of the TGF-beta signaling pathway in tumor cellsKlaus Podar, Noopur Raje, Kenneth C Anderson
Journal of Oncology|August 31, 2011
Targeting the tumor microenvironment: focus on angiogenesisFengjuan Fan, Alexander Schimming, Dirk Jaeger, et al.
Expert Opinion on Emerging Drugs|July 23, 2019
Emerging protein kinase inhibitors for the treatment of multiple myelomaJudith Lind, Felix Czernilofsky, Sonia Vallet, et al.
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|June 13, 2017
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myelomaKlaus Podar, Martin Pecherstorfer
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C Anderson
Cancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C Anderson
Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C Anderson
Cell Cycle (Georgetown, Tex.)|March 14, 2007
Inhibition of VEGF signaling pathways in multiple myeloma and other malignanciesKlaus Podar, Kenneth C Anderson
Expert Opinion on Biological Therapy|September 1, 2017
Adoptive cell therapy in multiple MyelomaSonia Vallet, Martin Pecherstorfer, Klaus Podar
Cancer Treatment and Research|October 4, 2016
Targeting the Bone Marrow MicroenvironmentMichele Moschetta, Yawara Kawano, Klaus Podar
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Inhibition of the TGF-beta signaling pathway in tumor cellsKlaus Podar, Noopur Raje, Kenneth C Anderson
Journal of Oncology|August 31, 2011
Targeting the tumor microenvironment: focus on angiogenesisFengjuan Fan, Alexander Schimming, Dirk Jaeger, et al.
Expert Opinion on Emerging Drugs|July 23, 2019
Emerging protein kinase inhibitors for the treatment of multiple myelomaJudith Lind, Felix Czernilofsky, Sonia Vallet, et al.
Pageof 15